MedPath

Contraceptive pill and hormonal vaginal ring in women with PCOS.

Phase 1
Conditions
Polycystic Ovary Syndrome (PCOS)
Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]
Registration Number
EUCTR2012-002220-32-FI
Lead Sponsor
OYS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Female
Target Recruitment
42
Inclusion Criteria

women aged between 18 to 40 years
-diagnosed PCOS (Rotterdam criteria)
-healthy, no medications
-no use of hormonal contraceptives or wash-out period of at least two months
-no contraindications to hormonal contraception

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 42
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-regular smoking
-excessive alcohol use
-pregnancy or breastfeeding
-oversensitivity to active ingredients
-migraine with focal aura
-severe or multiple risk factors to thrombosis
-diagnosed or suspected cancer
-diagnosed or suspected estrogen-dependent tumor
-acute or chronic hepatocellular disease –related abnormal liver function
-hepatic adenomas or carcinomas
-undiagnosed abnormal vaginal bleeding

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: to investigate the effects of vaginal and oral contraceptives on androgen secretion, insulin and glucose metabolism, lipid profile, and serum levels of SHBG and hs-CRP in women with PCOS. ;Secondary Objective: to investigate the effects after long term use and whether these contraceptives can be recommended to some group of women;Primary end point(s): Change in MATSUDA-index (1,65);Timepoint(s) of evaluation of this end point: After one year's use
Secondary Outcome Measures
NameTimeMethod
Secondary end point(s): Other changes in hormonal, metabolic or inflammatory parameters;Timepoint(s) of evaluation of this end point: After one year's use
© Copyright 2025. All Rights Reserved by MedPath